Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Aro Biotherapeutics has raised $41.5M in total funding. The most recent round was Series B. The last funding was announced in November 2023.
Aro Biotherapeutics's investors include HealthCap, Ionis Pharmaceuticals, Johnson & Johnson Innovation JJDC, Northpond Ventures, Cowen Healthcare Investments.
Aro Biotherapeutics is headquartered in Philadelphia, United States.
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Aro Biotherapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aro Biotherapeutics — Funding & Investors." VCBacked, November 28, 2023, https://www.vcbacked.co/company/aro-biotherapeutics. Accessed July 31, 2026.
VCBacked. (2023). Aro Biotherapeutics — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/aro-biotherapeutics
{{cite web |title=Aro Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aro-biotherapeutics |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated